Clinical Trial Update: MCS110 With BRAF/MEK Inhibition in Patients With Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Dana-Farber Cancer Institute reported results from a Phase 1/2 trial evaluating MCS110 in combination with BRAF/MEK inhibitors for melanoma. The trial is comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MCS110

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-07-31